Loading clinical trials...
Loading clinical trials...
Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia
Conditions
Interventions
Cladribine
Guadecitabine
+1 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
April 4, 2014
Primary Completion Date
November 24, 2020
Completion Date
November 24, 2020
Last Updated
August 27, 2024
NCT02835222
NCT02159495
NCT01822015
NCT02122081
NCT01806571
NCT00352365
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions